Here is the design of a clinical trial:

Official Title: Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions

Included conditions:
- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
- HER2 Negative Breast Carcinoma
- Hormone Receptor Positive Breast Carcinoma
- Invasive Breast Carcinoma
- Prognostic Stage I Breast Cancer AJCC v8
- Prognostic Stage II Breast Cancer AJCC v8
- Prognostic Stage III Breast Cancer AJCC v8

Study Armgroups:
- {'label': 'Arm I (TMR)', 'type': 'EXPERIMENTAL', 'description': 'Patients receive online educational information about ET at the start of their ET medication. Patients also receive daily text message reminders to take their ET medication and monthly text messages about how they are doing with taking their ET medication. These text messages continue for 9 months.', 'interventionNames': ['Other: Educational Intervention', 'Other: Text Message-based Navigation Intervention', 'Other: Questionnaire Administration', 'Other: Quality-of-Life Assessment']}
- {'label': 'Arm II (MI)', 'type': 'EXPERIMENTAL', 'description': 'Patients receive online educational information about ET at the start of their ET medication. Patients also receive a total of 5 motivational interviewing counseling sessions via telephone over 30-90 minutes for up to 9 months. These sessions are designed to support patients while they take their ET medication, develop health goals, and stay on track in achieving those goals.', 'interventionNames': ['Other: Educational Intervention', 'Behavioral: Motivational Interviewing', 'Other: Questionnaire Administration', 'Other: Quality-of-Life Assessment']}
- {'label': 'Arm III (TMR + MI)', 'type': 'EXPERIMENTAL', 'description': 'Patients receive online educational information about ET at the start of their ET medication. Patients also receive text messages as in Arm I and motivational interviewing counseling sessions as in Arm II.', 'interventionNames': ['Other: Educational Intervention', 'Other: Text Message-based Navigation Intervention', 'Behavioral: Motivational Interviewing', 'Other: Questionnaire Administration', 'Other: Quality-of-Life Assessment']}
- {'label': 'Arm IV (enhanced usual care)', 'type': 'ACTIVE_COMPARATOR', 'description': 'Patients attend usual care clinic visits every 3-6 months and receive online educational information about ET at the start of their ET medication. Patients also receive optional online information about living a healthy life after breast cancer.', 'interventionNames': ['Other: Educational Intervention', 'Other: Best Practice', 'Other: Questionnaire Administration', 'Other: Quality-of-Life Assessment']}

Interventions:
- {'type': 'OTHER', 'name': 'Educational Intervention', 'description': 'Receive online educational information about ET medication', 'armGroupLabels': ['Arm I (TMR)', 'Arm II (MI)', 'Arm III (TMR + MI)', 'Arm IV (enhanced usual care)']}
- {'type': 'OTHER', 'name': 'Text Message-based Navigation Intervention', 'description': 'Receive text messages', 'armGroupLabels': ['Arm I (TMR)', 'Arm III (TMR + MI)']}
- {'type': 'BEHAVIORAL', 'name': 'Motivational Interviewing', 'description': 'Receive motivational interviewing counseling sessions', 'armGroupLabels': ['Arm II (MI)', 'Arm III (TMR + MI)']}
- {'type': 'OTHER', 'name': 'Best Practice', 'description': 'Attend usual care clinic visits', 'armGroupLabels': ['Arm IV (enhanced usual care)'], 'otherNames': ['Standard of Care']}
- {'type': 'OTHER', 'name': 'Questionnaire Administration', 'description': 'Ancillary studies', 'armGroupLabels': ['Arm I (TMR)', 'Arm II (MI)', 'Arm III (TMR + MI)', 'Arm IV (enhanced usual care)']}
- {'type': 'OTHER', 'name': 'Quality-of-Life Assessment', 'description': 'Ancillary studies', 'armGroupLabels': ['Arm I (TMR)', 'Arm II (MI)', 'Arm III (TMR + MI)', 'Arm IV (enhanced usual care)']}

Primary Outcomes:
- {'measure': 'Endocrine therapy (ET) adherence at 12 months post-randomization', 'description': 'ET adherence at 12 months post-randomization will be measured by electronic pill monitoring cap (Pillsy-reported) and defined as the proportion of patients within each arm who have taken their ET medication for at least 292 of 365 days.', 'timeFrame': 'At 12 months post-randomization'}

Please estimate the sample size based on the assumption: 
The study maintains a primary family-wise two-sided type I error rate of α = 0.05, with two chi-square tests conducted at a nominal α = 0.025. The study aims for at least 80% power at a 2.5% two-sided significance level. An 11% ineligible and loss to follow-up rate is anticipated.
Sample size
        Enhanced usual care adherence at 12Â months is assumed to be 69%, based on our preliminary studies of pharmacy refill data from claims in Medicare, Medicaid, and private insurance populations, using weighted estimates of 12-month adherence among Black womenâ<â50Â years old, non-Black womenâ<â50Â years old, Black womenââ¥â50Â years old, and non-Black womenââ¥â50Â years old. We hypothesize 81% adherence for the TMR-only and MI-only intervention arms based on preliminary data from the GETSET MI counseling pilot intervention [37, 45]. To maintain a primary family-wise two-sided type I error rate of Î±â=â0.05, the two chi-square tests will be conducted with nominal Î±â=â0.025. At a 2.5% two-sided significance level, the study will have at least 80% power to detect differences in adherence (81% in single component intervention arms vs 69% in enhanced usual care) if 263 evaluable patients are randomized each to the TMR-only, MI-only, and enhanced usual care arms. Because we anticipate ineligible and loss to follow-up of approximately 11%, consistent with other clinical trials of cancer survivors, we will over-recruit, rendering a recruitment target of 1180 randomized patients total (295 per arm). Power Analysis and Sample Size (PASS) software (PASS v15, NCSS, Kaysville, UT) was used to conduct the power analysis.
        Young age and self-reported Black race have been shown to be risk factors for low ET adherence [13, 19, 20]. As such, the study is designed to accrue 30% (or 354 of 1180) of patients who self-identify as Black as well as 30% who areâ<â50Â years old at time of recruitment. Additionally, the ideal case is for race and age to be uncorrelated with one another so that they have independent effects on the outcome of interest. To achieve this, we have defined distinct accrual targets for four non-overlapping groups (i.e., Black womenâ<â50Â years old, non-Black womenâ<â50Â years old, Black womenââ¥â50Â years old, and non-Black womenââ¥â50Â years old) and close accrual for each group independently. The target accrual numbers for each group are shown in Table 2.
Table 2Accrual targets by race and age strataAge (years)BlackNon-BlackTotalâ<â50106248354ââ¥â50248578826Total3548261180